A patient treated with the multiple sclerosis (MS) drug Gilenya (fingolimod) has developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy (PML), the Food and Drug Administration (FDA) warned. This is the first case of PML reported following the administration of Gilenya in a patient who had not previously received Tysabri (natalizumab), an MS drug that is associated with a higher risk of PML. PML is a rare and serious brain infection caused by the John Cunningham (JC) virus that damages the fatty covering of the brain called the myelin. PML is usually leads to death or ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.